Authors and Disclosures
Emma Flanagan1,2, Ralley Prentice1,3,5, Emily K. Wright1,2, Peter R. Gibson4,5, Alyson L. Ross1, Jakob Begun6, Miles P. Sparrow4,5, Rimma Goldberg3,5, Ourania Rosella4, Megan Burns3, Katerina V. Kiburg7 and Sally J. Bell2,3,5
1Department of Gastroenterology, St Vincent's Hospital Melbourne Pty Ltd, Melbourne, Australia
2University of Melbourne, Melbourne, Australia
3Department of Gastroenterology, Monash Health, Melbourne, Australia
4Department of Gastroenterology, Alfred Health, Melbourne, Australia
5Monash University, Clayton, Australia
6Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Australia
7Department of Medicine, St Vincent's Hospital Melbourne Pty Ltd, Melbourne, Australia
Correspondence
Dr Ralley Prentice, Department of Gastroenterology, Monash Health, 246 Clayton rd, Clayton, Vic 3168 Australia. Email: ralley.prentice@monashhealth.org
Author Contributions
Emma Flanagan contributed to the design of the study, acquisition of data and critically reviewed the manuscript. Ralley Prentice contributed to the acquisition and interpretation of data and drafted the manuscript. Emily Wright contributed to the acquisition and interpretation of data and critically revised the manuscript. Peter Gibson contributed to the interpretation of data and critical revision of the manuscript. Miles Sparrow, Jakob Begun, Rimma Goldberg and Ourania Rosella contributed to the acquisition of data and critical revision of the manuscript. Katerina Kiburg contributed to the statistical analysis and interpretation of data. Alyson Ross and Megan Burns contributed to the acquisition of data. Sally Bell contributed to the conception and design of the study, acquisition and interpretation of data and critical revision of the manuscript. All authors approved the final manuscript, including the authorship list.
Declaration of personal interests
Peter Gibson has served as a consultant or advisory board member for Anatara, Atmo Biosciences, Falk Pharma, Immunic Therapeutics, Janssen, Novozymes, Pfizer and Takeda. He has received research grants for investigator-driven studies from Atmo Biosciences. He holds shares in Atmo Biosciences. Miles Sparrow has received educational grants or research support from Ferring, Orphan and Gilead; speaker's fees from Janssen, Abbvie, Ferring, Takeda, Pfizer and Shire; and served on advisory boards for Janssen, Takeda, Pfizer, Celgene, Abbvie, MSD and Emerge Health. Jakob Begun has received educational grants or research support from Ferring, Janssen and Pfizer; speaker's fees from Janssen, Abbvie, Ferring, Takeda, Pfizer and Chiesi; and served on advisory boards for Janssen, Takeda, Pfizer, Celgene, Abbvie, MSD, BMS and Chiesi. Sally Bell has received consultation fees from AbbVie and Janssen, has received research grants for other investigator-driven studies/clinical trial funding from AbbVie, Janssen and Shire and has received speaker's fees from AbbVie and Janssen. The other authors disclose no conflicts.